TWI463993B - Ｉｌ-２３及ｉｌ-１７拮抗劑於治療自體免疫眼發炎疾病之用途 - Google Patents
Ｉｌ-２３及ｉｌ-１７拮抗劑於治療自體免疫眼發炎疾病之用途 Download PDFInfo
- Publication number
- TWI463993B TWI463993B TW101115664A TW101115664A TWI463993B TW I463993 B TWI463993 B TW I463993B TW 101115664 A TW101115664 A TW 101115664A TW 101115664 A TW101115664 A TW 101115664A TW I463993 B TWI463993 B TW I463993B
- Authority
- TW
- Taiwan
- Prior art keywords
- antagonist
- monoclonal antibody
- activity
- antibody fragment
- antibody
- Prior art date
Links
- 230000001363 autoimmune Effects 0.000 title claims abstract description 21
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 18
- 239000005557 antagonist Substances 0.000 title claims description 105
- 108050003558 Interleukin-17 Proteins 0.000 claims abstract description 110
- 102000013691 Interleukin-17 Human genes 0.000 claims abstract description 108
- 102000013264 Interleukin-23 Human genes 0.000 claims abstract description 101
- 108010065637 Interleukin-23 Proteins 0.000 claims abstract description 101
- 230000000694 effects Effects 0.000 claims abstract description 54
- 206010046851 Uveitis Diseases 0.000 claims description 35
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 29
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 29
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 claims description 27
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 claims description 26
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims description 23
- 206010061218 Inflammation Diseases 0.000 claims description 22
- 230000004054 inflammatory process Effects 0.000 claims description 22
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 101001003142 Homo sapiens Interleukin-12 receptor subunit beta-1 Proteins 0.000 claims description 16
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 claims description 16
- 229940124597 therapeutic agent Drugs 0.000 claims description 16
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims description 10
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 9
- 230000001684 chronic effect Effects 0.000 claims description 8
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 claims description 5
- 208000018359 Systemic autoimmune disease Diseases 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 5
- 208000002574 reactive arthritis Diseases 0.000 claims description 5
- 150000003431 steroids Chemical class 0.000 claims description 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 208000033464 Reiter syndrome Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 208000027496 Behcet disease Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000006379 syphilis Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 37
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 4
- 229940126534 drug product Drugs 0.000 abstract description 2
- 229940124829 interleukin-23 Drugs 0.000 description 85
- 238000011282 treatment Methods 0.000 description 72
- 210000001508 eye Anatomy 0.000 description 55
- 102000004127 Cytokines Human genes 0.000 description 38
- 108090000695 Cytokines Proteins 0.000 description 38
- 108090000765 processed proteins & peptides Proteins 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 37
- 239000000427 antigen Substances 0.000 description 34
- 102000036639 antigens Human genes 0.000 description 34
- 108091007433 antigens Proteins 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 30
- 230000027455 binding Effects 0.000 description 29
- 238000009739 binding Methods 0.000 description 28
- 201000010099 disease Diseases 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 25
- 101710186083 Interleukin-17 receptor A Proteins 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 229920001184 polypeptide Polymers 0.000 description 19
- 101710137010 Retinol-binding protein 3 Proteins 0.000 description 18
- 102100038247 Retinol-binding protein 3 Human genes 0.000 description 18
- 102100035012 Interleukin-17 receptor C Human genes 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- 101710186068 Interleukin-17 receptor C Proteins 0.000 description 16
- 230000003053 immunization Effects 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- 230000002757 inflammatory effect Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 108010074328 Interferon-gamma Proteins 0.000 description 11
- 102000013462 Interleukin-12 Human genes 0.000 description 11
- 108010065805 Interleukin-12 Proteins 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 229940117681 interleukin-12 Drugs 0.000 description 11
- 102100037850 Interferon gamma Human genes 0.000 description 10
- 230000002411 adverse Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 210000002159 anterior chamber Anatomy 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 238000006386 neutralization reaction Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- 206010022941 Iridocyclitis Diseases 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 201000004612 anterior uveitis Diseases 0.000 description 6
- 210000004240 ciliary body Anatomy 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 208000002691 Choroiditis Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000003971 Posterior uveitis Diseases 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 201000004982 autoimmune uveitis Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- -1 flurometholone Chemical compound 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101001019598 Homo sapiens Interleukin-17 receptor A Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000816 peptidomimetic Substances 0.000 description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 3
- 206010015943 Eye inflammation Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000003161 choroid Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 108040001304 interleukin-17 receptor activity proteins Proteins 0.000 description 3
- 102000053460 interleukin-17 receptor activity proteins Human genes 0.000 description 3
- 108010048996 interstitial retinol-binding protein Proteins 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 description 2
- 101001019602 Homo sapiens Interleukin-17 receptor C Proteins 0.000 description 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000010799 Receptor Interactions Effects 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229940123468 Transferase inhibitor Drugs 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229960004669 basiliximab Drugs 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 201000007717 corneal ulcer Diseases 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 201000004356 excessive tearing Diseases 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000005210 lymphoid organ Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000003558 transferase inhibitor Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 206010003253 Arthritis enteropathic Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011033 Corneal oedema Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 206010052119 Cyclitic membrane Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 206010073423 Eye ulcer Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001128158 Homo sapiens Nanos homolog 2 Proteins 0.000 description 1
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 1
- 102000014154 Interleukin-12 Subunit p35 Human genes 0.000 description 1
- 108010011301 Interleukin-12 Subunit p35 Proteins 0.000 description 1
- 101710103841 Interleukin-12 receptor subunit beta-1 Proteins 0.000 description 1
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- 238000001265 Jonckheere trend test Methods 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000010175 Opsin Human genes 0.000 description 1
- 108050001704 Opsin Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 101000737809 Rattus norvegicus Cadherin-related family member 5 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 201000004778 corneal edema Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000005858 glycosidation reaction Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000047144 human IL12RB1 Human genes 0.000 description 1
- 102000053162 human IL17A Human genes 0.000 description 1
- 102000043448 human IL17RA Human genes 0.000 description 1
- 102000057111 human IL23R Human genes 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000011283 initial treatment period Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002577 ophthalmoscopy Methods 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 201000007407 panuveitis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 208000002440 photoallergic dermatitis Diseases 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000002301 subretinal fluid Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000008400 supply water Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000001745 uvea Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71379205P | 2005-09-01 | 2005-09-01 | |
| US83731206P | 2006-08-11 | 2006-08-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201235050A TW201235050A (en) | 2012-09-01 |
| TWI463993B true TWI463993B (zh) | 2014-12-11 |
Family
ID=37686002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095132202A TWI372061B (en) | 2005-09-01 | 2006-08-31 | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease |
| TW101115664A TWI463993B (zh) | 2005-09-01 | 2006-08-31 | Ｉｌ-２３及ｉｌ-１７拮抗劑於治療自體免疫眼發炎疾病之用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095132202A TWI372061B (en) | 2005-09-01 | 2006-08-31 | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US20080199460A1 (enExample) |
| EP (3) | EP2116258A1 (enExample) |
| JP (3) | JP2009507023A (enExample) |
| CN (1) | CN101296706B (enExample) |
| AT (1) | ATE445415T1 (enExample) |
| AU (1) | AU2006284841B2 (enExample) |
| BR (1) | BRPI0615297A2 (enExample) |
| CA (1) | CA2621086A1 (enExample) |
| CY (1) | CY1110606T1 (enExample) |
| DE (1) | DE602006009834D1 (enExample) |
| DK (1) | DK1933869T3 (enExample) |
| ES (1) | ES2333260T3 (enExample) |
| HR (1) | HRP20100014T1 (enExample) |
| NO (1) | NO20081574L (enExample) |
| NZ (2) | NZ566424A (enExample) |
| PL (1) | PL1933869T3 (enExample) |
| PT (1) | PT1933869E (enExample) |
| RS (1) | RS51142B (enExample) |
| SI (1) | SI1933869T1 (enExample) |
| TW (2) | TWI372061B (enExample) |
| WO (1) | WO2007027761A2 (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| CA2631961A1 (en) | 2005-12-02 | 2007-11-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling relating to antibodies that bind to il-22 |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| AU2007260787A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc | IL-17 and IL-23 antagonists and methods of using the same |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| NZ579297A (en) * | 2007-02-28 | 2012-03-30 | Schering Corp | Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders |
| EP2392597B1 (en) * | 2007-04-27 | 2014-04-02 | ZymoGenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| EP2174667B1 (en) * | 2007-07-26 | 2017-01-04 | Osaka University | Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient |
| US20110212100A1 (en) * | 2007-08-15 | 2011-09-01 | Tracy Keller | Methods for modulating development and expansion of il-17 expressing cells |
| EP2215125A1 (en) | 2007-11-27 | 2010-08-11 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| EP2242504B1 (en) * | 2008-01-09 | 2021-07-14 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of ocular inflammatory disorders |
| CN102037017B (zh) | 2008-02-21 | 2014-07-09 | 麒麟-安姆根有限公司 | Il-17ra-il-17rb拮抗物及其用途 |
| SG190626A1 (en) | 2008-05-05 | 2013-06-28 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
| WO2010081091A2 (en) * | 2009-01-09 | 2010-07-15 | Schepens Eye Research Institute | Therapeutic compositions for treatment of corneal disorders |
| US20120014970A1 (en) * | 2009-01-09 | 2012-01-19 | Reza Dana | Therapeutic Compositions for Treatment of Corneal Disorders |
| SG174891A1 (en) * | 2009-04-01 | 2011-11-28 | Genentech Inc | Treatment of insulin-resistant disorders |
| CN102458437B (zh) | 2009-05-05 | 2015-06-10 | 诺维莫尼公司 | 抗il-17f抗体及其使用方法 |
| WO2011033493A1 (en) | 2009-09-21 | 2011-03-24 | Conservatoire National des Arts et Métiers | Carrier conjugates of il-23-peptides and their induced antibodies |
| EA201891433A3 (ru) | 2010-01-15 | 2019-02-28 | Кирин-Эмджен, Инк. | Состав антитела и терапевтические режимы |
| US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
| US8853150B2 (en) | 2010-07-29 | 2014-10-07 | Eleven Biotherapeutics, Inc. | Chimeric IL-1 receptor type I antagonists |
| WO2012045848A1 (en) * | 2010-10-08 | 2012-04-12 | Novartis Ag | Methods of treating psoriasis using il-17 antagonists |
| PT2635601T (pt) | 2010-11-04 | 2016-09-27 | Boehringer Ingelheim Int | Anticorpos anti-il-23 |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| WO2013059644A1 (en) * | 2011-10-21 | 2013-04-25 | Baylor College Of Medicine | Method to measure inflammation in the conjunctiva of patients with tear dysfunction |
| US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
| EP2834273B1 (en) | 2012-04-05 | 2018-08-22 | F.Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| EP4039275A1 (en) | 2012-05-03 | 2022-08-10 | Boehringer Ingelheim International GmbH | Anti-il-23p19 antibodies |
| SI2852615T1 (sl) | 2012-05-22 | 2019-02-28 | Bristol-Myers Squibb Company | IL-17A/F IL-23 bispecifična protitelesa in njihova uporaba |
| US20150307606A1 (en) * | 2012-12-13 | 2015-10-29 | Ashwin Basarkar | Lyophilized spherical pellets of anti-il-23 antibodies |
| WO2014107737A2 (en) * | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Local delivery of il-17 inhibitors for treating ocular disease |
| SG10201707477SA (en) | 2013-03-13 | 2017-10-30 | Eleven Biotherapeutics Inc | Chimeric cytokine formulations for ocular delivery |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| US9603882B2 (en) | 2013-08-13 | 2017-03-28 | Industrial Technology Research Institute | Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells |
| US10507241B2 (en) | 2014-07-24 | 2019-12-17 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of IL-23A related diseases |
| EA039598B9 (ru) | 2014-09-03 | 2022-03-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединение, нацеленное на ил-23а и фно-альфа, и его применение |
| AR102417A1 (es) * | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CA2970234A1 (en) | 2014-12-23 | 2016-06-30 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| EA202090948A1 (ru) | 2014-12-23 | 2020-11-30 | 4Д Фарма Рисерч Лимитед | Иммуномодуляция |
| US10058705B2 (en) | 2014-12-31 | 2018-08-28 | Micron Devices Llc | Antenna assembly |
| CN107407677B (zh) * | 2015-01-28 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 多发性硬化的基因表达标志和治疗 |
| IL307578A (en) | 2015-02-04 | 2023-12-01 | Boehringer Ingelheim Int | Methods of treating inflammatory diseases |
| CN104725514A (zh) * | 2015-02-06 | 2015-06-24 | 中国药科大学 | 新型il23拮抗剂 |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA55434B1 (fr) | 2015-06-15 | 2022-02-28 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| PT3240554T (pt) | 2015-06-15 | 2019-11-04 | 4D Pharma Res Ltd | Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| PT3307288T (pt) | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| HK1258292A1 (zh) * | 2015-09-17 | 2019-11-08 | Amgen Inc. | 使用il23途徑生物標誌物預測il23拮抗劑的臨床應答 |
| BR112018010089A2 (pt) | 2015-11-20 | 2018-11-13 | 4D Pharma Res Ltd | composições compreendendo cepas bacterianas |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) * | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| AU2017226831B2 (en) | 2016-03-04 | 2018-10-04 | 4D Pharma Plc | Compositions comprising bacterial Blautia strains for treating visceral hypersensitivity |
| TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| HUE054164T2 (hu) | 2017-05-22 | 2021-08-30 | 4D Pharma Res Ltd | Baktériumtörzseket tartalmazó készítmények |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| PL3600363T3 (pl) | 2017-06-14 | 2021-06-14 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| JP6884889B2 (ja) | 2017-06-14 | 2021-06-09 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| SMT202000555T1 (it) | 2017-06-14 | 2020-11-10 | 4D Pharma Res Limited | Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi |
| US11859001B2 (en) | 2020-08-05 | 2024-01-02 | Synthekine, Inc. | IL12RB1-Binding molecules and methods of use |
| WO2022031890A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Ifngr2 binding molecules and methods of use |
| WO2022032023A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il23r binding molecules and methods of use |
| EP4192502A4 (en) | 2020-08-05 | 2024-10-09 | Synthekine, Inc. | Compositions and methods related to il27 receptor binding |
| KR20230061391A (ko) | 2020-08-05 | 2023-05-08 | 신테카인, 인크. | gp130 결합 분자 및 사용 방법 |
| WO2022032042A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il12 receptor synthetic cytokines and methods of use |
| US12122839B2 (en) | 2020-08-05 | 2024-10-22 | Synthekine, Inc. | IFNGR binding synthetic cytokines and methods of use |
| WO2022032006A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rb binding molecules and methods of use |
| WO2022032022A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il10 receptor binding molecules and methods of use |
| WO2022031870A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | IL27Rα BINDING MOLECULES AND METHODS OF USE |
| US12286482B2 (en) | 2020-08-05 | 2025-04-29 | Synthekine, Inc. | IL10RB binding molecules and encoding nucleic acids |
| WO2022031884A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rg binding molecules and methods of use |
| US20240026014A1 (en) * | 2020-08-05 | 2024-01-25 | Synthekine, Inc. | Compositions and methods related to receptor pairings |
| CN116322754A (zh) | 2020-08-05 | 2023-06-23 | 辛德凯因股份有限公司 | Il10ra结合分子及使用方法 |
| KR20240082379A (ko) * | 2021-10-03 | 2024-06-10 | 시스트이뮨, 인코포레이티드 | 암 치료 방법 및 이의 약제학적 조성물 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040219150A1 (en) * | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| ATE452975T1 (de) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ATE204325T1 (de) | 1993-04-29 | 2001-09-15 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US6680057B1 (en) * | 1995-03-23 | 2004-01-20 | Immunex Corporation | Methods of treating autoimmune disease by administering interleukin-17 receptor |
| MX9707021A (es) | 1995-03-23 | 1997-11-29 | Immunex Corp | Receptor de il-7. |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6326482B1 (en) | 1999-04-23 | 2001-12-04 | Genentech, Inc. | SH2 domain-containing peptides |
| JP2002531466A (ja) | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス， インコーポレイテッド | γ−インターフェロンに対するヒト化抗体 |
| MXPA02012743A (es) | 2000-06-22 | 2003-04-25 | Amgen Inc | Moleculas tipo il-17 y usos de las mismas. |
| WO2002097048A2 (en) | 2001-05-30 | 2002-12-05 | Centocor, Inc. | ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
| US20050154046A1 (en) | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| KR101053412B1 (ko) * | 2002-10-30 | 2011-08-01 | 제넨테크, 인크. | Ｉｌ―１７ 생성의 억제 |
| BRPI0408247A (pt) | 2003-03-10 | 2006-03-01 | Schering Corp | usos de antagonistas e agonistas de il-23 e reagentes relacionados |
| CA2525184C (en) * | 2003-05-09 | 2012-10-30 | Centocor, Inc. | Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
| US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
| EP2784084B2 (en) | 2003-07-08 | 2023-10-04 | Novartis Pharma AG | Antagonist antibodies to IL-17A/F heterologous polypeptides |
| US7501247B2 (en) * | 2004-05-03 | 2009-03-10 | Schering Corporation | Method of treating skin inflammation |
| US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| DE602005022871D1 (de) | 2004-06-07 | 2010-09-23 | Univ Ramot | Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko |
| JP2008505080A (ja) * | 2004-07-01 | 2008-02-21 | ニューヨーク ユニバーシティー | ＲＯＲγｔ機能の調節のための組成物および方法 |
| DE102005032499B4 (de) * | 2004-07-13 | 2009-10-22 | Lg Electronics Inc. | Dämpfer zur Vibrationsdämpfung und damit ausgerüstete Waschmaschine |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
| EP1827447A1 (en) * | 2004-11-19 | 2007-09-05 | Synta Pharmaceuticals Corporation | Pyrimidine compounds and uses thereof |
| CA2588449A1 (en) * | 2004-11-24 | 2006-06-01 | Therakine Corporation | An implant for intraocular drug delivery |
| US7820168B2 (en) * | 2004-12-20 | 2010-10-26 | Schering Corporation | Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17 |
| AR051805A1 (es) | 2004-12-21 | 2007-02-07 | Centocor Inc | Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos |
| CA2596509A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor |
| CN103145839A (zh) | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| EP3501537A1 (en) * | 2005-06-30 | 2019-06-26 | Janssen Biotech, Inc. | Anti-il23 antibodies, compositions, methods and uses |
| SG165322A1 (en) | 2005-08-31 | 2010-10-28 | Schering Corp | Engineered anti-il-23 antibodies |
| JP5193881B2 (ja) | 2005-12-29 | 2013-05-08 | セントカー・インコーポレーテツド | ヒト抗ｉｌ−２３抗体、組成物、方法および用途 |
| TW200815469A (en) * | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
-
2006
- 2006-08-30 WO PCT/US2006/033840 patent/WO2007027761A2/en not_active Ceased
- 2006-08-30 BR BRPI0615297-0A patent/BRPI0615297A2/pt not_active IP Right Cessation
- 2006-08-30 AT AT06813945T patent/ATE445415T1/de active
- 2006-08-30 EP EP09164605A patent/EP2116258A1/en not_active Withdrawn
- 2006-08-30 EP EP06813945A patent/EP1933869B1/en not_active Revoked
- 2006-08-30 HR HR20100014T patent/HRP20100014T1/hr unknown
- 2006-08-30 US US11/512,622 patent/US20080199460A1/en not_active Abandoned
- 2006-08-30 DE DE602006009834T patent/DE602006009834D1/de active Active
- 2006-08-30 PL PL06813945T patent/PL1933869T3/pl unknown
- 2006-08-30 ES ES06813945T patent/ES2333260T3/es active Active
- 2006-08-30 EP EP10180648.7A patent/EP2322219A3/en not_active Withdrawn
- 2006-08-30 AU AU2006284841A patent/AU2006284841B2/en not_active Ceased
- 2006-08-30 CN CN2006800403078A patent/CN101296706B/zh not_active Expired - Fee Related
- 2006-08-30 PT PT06813945T patent/PT1933869E/pt unknown
- 2006-08-30 NZ NZ566424A patent/NZ566424A/en not_active IP Right Cessation
- 2006-08-30 CA CA002621086A patent/CA2621086A1/en not_active Abandoned
- 2006-08-30 NZ NZ595262A patent/NZ595262A/xx not_active IP Right Cessation
- 2006-08-30 DK DK06813945.0T patent/DK1933869T3/da active
- 2006-08-30 JP JP2008529228A patent/JP2009507023A/ja not_active Withdrawn
- 2006-08-30 RS RSP-2009/0529A patent/RS51142B/sr unknown
- 2006-08-30 SI SI200630517T patent/SI1933869T1/sl unknown
- 2006-08-31 TW TW095132202A patent/TWI372061B/zh not_active IP Right Cessation
- 2006-08-31 TW TW101115664A patent/TWI463993B/zh not_active IP Right Cessation
-
2008
- 2008-03-31 NO NO20081574A patent/NO20081574L/no not_active Application Discontinuation
-
2009
- 2009-12-21 US US12/643,166 patent/US20100111954A1/en not_active Abandoned
- 2009-12-21 US US12/643,152 patent/US8524230B2/en not_active Expired - Fee Related
-
2010
- 2010-01-12 CY CY20101100034T patent/CY1110606T1/el unknown
-
2011
- 2011-01-28 US US13/015,900 patent/US20110142831A1/en not_active Abandoned
- 2011-06-28 JP JP2011143593A patent/JP5462838B2/ja not_active Expired - Fee Related
-
2013
- 2013-08-06 US US13/960,441 patent/US20130323251A1/en not_active Abandoned
- 2013-08-13 JP JP2013168006A patent/JP2014005285A/ja active Pending
-
2014
- 2014-05-12 US US14/274,905 patent/US20140248279A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040219150A1 (en) * | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI463993B (zh) | Ｉｌ-２３及ｉｌ-１７拮抗劑於治療自體免疫眼發炎疾病之用途 | |
| EP2056838B1 (en) | Combination therapy for treatment of immune disorders | |
| WO2016031250A1 (en) | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy | |
| US20230203149A1 (en) | Treatment of atopic dermatitis | |
| HK1119578B (en) | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease | |
| HK1152251A (en) | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease | |
| HK1134655A (en) | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease | |
| US20200048339A1 (en) | Use of il-20 antagonists for treating eye diseases | |
| AU2014200946A1 (en) | Combination therapy for treatment of immune disorders | |
| HK1167104A (en) | Combination therapy for treatment of immune disorders | |
| HK1167100A (en) | Combination therapy for treatment of immune disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |